Innovent Biologics

Pharmaceutical ManufacturingJiangsu, China501-1000 Employees

Innovent Biologics, based in Suzhou, Jiangsu, China, is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative medicines for cancer and other major diseases, with a pipeline spanning oncology, metabolic, autoimmune, and related areas. The company operates a fully integrated platform that covers research and development, chemistry, manufacturing and controls, clinical development, and commercialization, enabling end-to-end progression of therapies. Four products have been approved for marketing in China, including TYVYT (sintilimab), BYVASDA (bevacizumab), SULINNO (adalimumab), and HALPRYZA (rituximab); the pipeline also includes multiple assets in late-stage trials and many in earlier clinical stages. Innovent maintains a production facility that adheres to cGMP standards aligned with NMPA, FDA, and EMA, with GMP audits conducted by international partners, and has assembled an international team of experts. In 2026, Innovent entered into a global licensing and collaboration agreement with Pfizer to co-develop a portfolio of 12 cancer programs, signaling ongoing momentum in its late-stage oncology efforts.

Sign up for free to view info

Email Format Employee directory